Medical Devices US

US Wound Care Biologics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Wound Care Biologics Market Industry Trends and Forecast to 2034: Segmented by (Product, Wound, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.04 Bn Placeholder estimate
Estimate 2025 $1.10 Bn 42.9% of the global market
Projected 2034 $1.91 Bn 73.3% Adds $806.7 Mn over 9 forecast years
CAGR 2025–2034 6.3% Faster than 47% of 173 Medical Devices markets here
Key players 5
  • US is 42.89% of the global market.
  • In North America, the largest is US (this report) at $1.10 Bn.
  • Fastest growing: Canada at 7.9% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$806.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Wound Care Biologics Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.04 Bn — —
2025 (base) $1.10 Bn +$65.2 Mn —
2026 (forecast) $1.17 Bn +$69.3 Mn +6.3%
2027 (forecast) $1.24 Bn +$73.7 Mn +13%
2028 (forecast) $1.32 Bn +$78.3 Mn +20.1%
2029 (forecast) $1.41 Bn +$83.3 Mn +27.7%
2030 (forecast) $1.49 Bn +$88.5 Mn +35.7%
2031 (forecast) $1.59 Bn +$94.1 Mn +44.3%
2032 (forecast) $1.69 Bn +$100.0 Mn +53.4%
2033 (forecast) $1.79 Bn +$106.3 Mn +63%
2034 (forecast) $1.91 Bn +$113.0 Mn +73.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Wound Care Biologics Market Analysis at a glance
Market size, 2025$1.10 Bn placeholder estimate
Forecast, 2034$1.91 Bn placeholder estimate
Growth (CAGR), 2025–20346.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, wound and end user (see all)
Key playersOrganogenesis, MiMedx, Smith & Nephew, Integra Life Sciences Corporation, Vericel (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Wound Care Biologics Market Analysis Executive Summary

Wound care biologics use living or natural materials such as skin substitutes and growth factors to heal hard-to-heal wounds.

Key segments of the wound Care Biologics market include product (Skin Substitutes, Growth Factors and Amniotic Membranes) and wound (Diabetic Foot Ulcers, Venous Leg Ulcers and Burns).

Bar chart: US Wound Care Biologics market size, 2024–2034, placeholder estimates. $1.04 Bn in 2024, $1.10 Bn in 2025 and $1.91 Bn in 2034, 6.3% CAGR.
US Wound Care Biologics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Wound Care Biologics Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the wound Care Biologics market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the wound Care Biologics market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the wound Care Biologics market.

Competitive Landscape for Wound Care Biologics Market in the US

The wound Care Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Wound Care Biologics Market in the US

Wound Care Biologics in the US: rules and payment

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how wound Care Biologics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Wound Care Biologics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Wound Care Biologics in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Wound Care Biologics market in the US?
Placeholder estimate: about $1.10 Bn in 2025, rising to about $1.91 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Wound Care Biologics market in the US growing?
Placeholder estimate: about 6.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Wound Care Biologics market report cover?
The report splits the market by product (Skin Substitutes, Growth Factors, Amniotic Membranes, Collagen Products), wound (Diabetic Foot Ulcers, Venous Leg Ulcers, Burns, Pressure Ulcers) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Wound Care Biologics market?
Key players include Organogenesis, MiMedx, Smith & Nephew, Integra Life Sciences Corporation and Vericel.
What is driving the Wound Care Biologics market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the wound Care Biologics market.
Who regulates Wound Care Biologics in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How much research is published on Wound Care Biologics?
PubMed lists 8 papers on Wound Care Biologics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on wounds and burns and biologics and biosimilars

See the topic